CONTEXT: Pediatric cancer treatment may imply an increased risk of hypogonadism, leading to metabolic disorders and osteoporosis. Such complications are potentially preventable. OBJECTIVE: The aim of this study was to assess diagnosis- and treatment-dependent risk of hypogonadism in male childhood cancer survivors (CCS). DESIGN: Male CCS who were treated during the period 1970-2002 and who in 2004 were 18-45 yr of age were eligible. SETTING: The study was conducted in a university hospital clinic. PATIENTS: A consecutive group of CCS treated at Lund University Hospital was selected for the study, of whom 151 (38%) agreed to participate. Furthermore, 141 healthy fertile men served as controls. INTERVENTIONS: We measured serum levels of free and total testosterone, SHBG, and LH. MAIN OUTCOME MEASURES: Odds ratios (OR) for biochemical hypogonadism, defined as total testosterone less than 10 nmol/liter and/or LH above 10 IU/liter, were calculated and related to type of cancer, treatment received, as well as testicular volume. RESULTS: Hypogonadism was more commonly detected in CCS than in controls (OR, 6.7; 95% CI, 2.7, 17). The increased presence of hypogonadism was noted in the following treatment groups: brain surgery, chemotherapy (with and without radiotherapy), and testicular irradiation. Low total testicular volume (<or=24 ml) was associated with a high risk of hypogonadism (OR, 31; 95% CI, 11, 92). CONCLUSION: Adult male survivors of childhood cancer are at risk of hypogonadism, which should be acknowledged in the long-term follow-up of these men.
CONTEXT: Pediatric cancer treatment may imply an increased risk of hypogonadism, leading to metabolic disorders and osteoporosis. Such complications are potentially preventable. OBJECTIVE: The aim of this study was to assess diagnosis- and treatment-dependent risk of hypogonadism in male childhood cancer survivors (CCS). DESIGN: Male CCS who were treated during the period 1970-2002 and who in 2004 were 18-45 yr of age were eligible. SETTING: The study was conducted in a university hospital clinic. PATIENTS: A consecutive group of CCS treated at Lund University Hospital was selected for the study, of whom 151 (38%) agreed to participate. Furthermore, 141 healthy fertile men served as controls. INTERVENTIONS: We measured serum levels of free and total testosterone, SHBG, and LH. MAIN OUTCOME MEASURES: Odds ratios (OR) for biochemical hypogonadism, defined as total testosterone less than 10 nmol/liter and/or LH above 10 IU/liter, were calculated and related to type of cancer, treatment received, as well as testicular volume. RESULTS:Hypogonadism was more commonly detected in CCS than in controls (OR, 6.7; 95% CI, 2.7, 17). The increased presence of hypogonadism was noted in the following treatment groups: brain surgery, chemotherapy (with and without radiotherapy), and testicular irradiation. Low total testicular volume (<or=24 ml) was associated with a high risk of hypogonadism (OR, 31; 95% CI, 11, 92). CONCLUSION: Adult male survivors of childhood cancer are at risk of hypogonadism, which should be acknowledged in the long-term follow-up of these men.
Authors: Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544
Authors: Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger Journal: Lancet Diabetes Endocrinol Date: 2015-04-12 Impact factor: 32.069
Authors: Wassim Chemaitilly; Qi Liu; Laura van Iersel; Kirsten K Ness; Zhenghong Li; Carmen L Wilson; Tara M Brinkman; James L Klosky; Nicole Barnes; Karen L Clark; Rebecca M Howell; Susan A Smith; Matthew J Krasin; Monika L Metzger; Gregory T Armstrong; Michael W Bishop; Hanneke M van Santen; Ching-Hon Pui; Deo Kumar Srivastava; Yutaka Yasui; Melissa M Hudson; Leslie L Robison; Daniel M Green; Charles A Sklar Journal: J Clin Oncol Date: 2019-09-26 Impact factor: 44.544
Authors: C Pfitzer; C-M Chen; T Wessel; T Keil; A Sörgel; T Langer; D Steinmann; A Borgmann-Staudt Journal: J Cancer Res Clin Oncol Date: 2014-05-20 Impact factor: 4.553
Authors: Kamnesh R Pradhan; Yan Chen; Sogol Moustoufi-Moab; Kevin Krull; Kevin C Oeffinger; Charles Sklar; Gregory T Armstrong; Kirsten K Ness; Leslie Robison; Yutaka Yasui; Paul C Nathan Journal: J Clin Endocrinol Metab Date: 2019-11-01 Impact factor: 5.958
Authors: E Brignardello; F Felicetti; A Castiglione; A Nervo; E Biasin; G Ciccone; F Fagioli; A Corrias Journal: J Cancer Res Clin Oncol Date: 2016-02-10 Impact factor: 4.553